On Sept. 22, 2020, BioSig Technologies and its subsidiary, ViralClear Pharma announced that the size of the ongoing randomized, double-blind, placebo-controlled Phase 2 trial of merimepodib in combination with remdesivir is being increased from 40 to 80 subjects.